Pharma 5.0

BioDuro opens new Chinese automated solid-phase peptide synthesis scale-up facility

Published: 13-Jan-2025

The CRDMO's new scale-up laboratory in Shanghai will allow it to serve the increasing demand in the pharmaceutical industry for peptide manufacturing services

BioDuro has opened a new solid-phase peptide synthesis scale-up laboratory at the Shanghai Zhangjiang High-tech Park campus.

The novel facility — which is fully automated — will allow BioDuro to further cater to the demand for peptide manufacturing services.

Equipped with automated solid phase peptide synthesisers, cleavage systems and freeze-drying equipment, it is designed to support customers from across the globe in scaling up their peptide production processes up to 800 mmol.

The laboratory can produce a large range of peptide molecules, including linear and cyclic peptides, as well as peptide drug conjugates (PDCs). 

 

Expanding operations in China

To solidify its peptide manufacturing capabilities in China, BioDuro has opened the Shanghai centre to complement its peptide discovery centre in Beijing, which primarily focuses on early stage R&D.

This means the company can now work with partners in the APAC region and further afield to run peptide projects from discovery to development.

The team at both centres are solid-phase and liquid-phase peptide synthesis specialists, meaning they can provide flexibility to their clients and support the customisation of next-generation peptides for therapeutic purposes.

CEO of BioDuro, Dr Armin Spura, commented: “Demand for peptide-based programs has increased considerably, and the opening of this new laboratory provides BioDuro’s customers with a significant step forward in addressing the capabilities required to scale their candidates to compete in this fast-growing field,” 

“We remain committed to continuously advancing our CRDMO capabilities and capacity, driving breakthroughs that deliver life-changing therapies to patients worldwide.”

BioDuro’s comprehensive peptide platform integrates biology and Drug Metabolism and Pharmacokinetics (DMPK) services, offering a one-stop shop solution to accelerate peptide development.

This integrated approach is intended to ensure streamlined processes and efficient collaboration, helping clients bring innovative peptide therapeutics to market faster.

You may also like